Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MKC-442 Combination Therapy in HIV
NCT00002420Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Emivirine in human immunodeficiency virus infection (HIV), sponsored by Bristol Myers Squibb. Primary endpoints: Change from baseline in plasma HIV-1 RNA levels at 24 weeks, Change from baseline in lymphocyte subsets at 24 weeks and 1 more. Status: terminated.
02
Drugs
Emivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002420.